Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rasagiline
Drug ID BADD_D02441
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status approved
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D08469; D10829
MeSH ID C031967
PubChem ID 3052776
TTD Drug ID D06OMW
NDC Product Code 16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779
UNII 003N66TS6T
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C12H13N
CAS Registry Number 136236-51-6
SMILES C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Influenza like illness08.01.03.0100.003572%
Inguinal hernia07.16.02.0010.002436%Not Available
Insomnia17.15.03.002; 19.02.01.0020.013639%
Interstitial lung disease22.01.02.003; 10.02.01.0330.001624%Not Available
Intestinal obstruction07.13.01.0020.001624%Not Available
Lactic acidosis14.01.01.0020.002436%Not Available
Loss of consciousness17.02.04.0040.008119%Not Available
Lymphadenopathy01.09.01.0020.001624%Not Available
Malignant melanoma23.08.01.001; 16.03.01.0010.002436%Not Available
Marasmus14.03.02.0130.007307%Not Available
Melaena24.07.02.013; 07.12.02.0040.001624%Not Available
Mental impairment19.21.02.003; 17.03.03.0020.001624%Not Available
Metabolic acidosis14.01.01.0030.002436%Not Available
Movement disorder17.01.02.0100.005196%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.002436%Not Available
Musculoskeletal pain15.03.04.0070.004059%
Myocardial ischaemia24.04.04.010; 02.02.02.0080.001624%Not Available
Neoplasm malignant16.16.01.0010.004871%Not Available
Neuroendocrine carcinoma of the skin16.03.02.008; 05.08.01.009; 23.08.02.0080.001624%Not Available
Neurogenic bladder20.03.03.001; 17.10.01.0020.001624%Not Available
Nightmare19.02.03.0030.001624%Not Available
Obsessive-compulsive disorder19.06.05.0020.001624%Not Available
Obsessive-compulsive personality disorder19.05.04.0010.001624%Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.0110.002436%
On and off phenomenon17.01.05.0040.002436%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.024518%Not Available
Panic attack19.06.04.0010.002436%Not Available
Parkinsonism17.01.05.0030.006008%Not Available
Pemphigoid23.03.01.004; 10.04.02.0020.001624%Not Available
Personality change17.02.05.019; 19.05.01.0060.001624%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages